Surface Oncology To Test SRF388 Plus Keytruda Combo In Solid Tumor Settings

Surface Oncology Inc (NASDAQ: SURF) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Surface's SRF388 with the latter's Keytruda (pembrolizumab).

This combination will be studied as a component of the Phase 1 study of SRF388. It will be evaluated in patients with solid tumors, focusing on patients with liver cancer and kidney cancer.